SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer revenue guidance, a reduced advertising outlook, and concerns about slowing growth, prompting analyst downgrades and price-target cuts. Traders are split between viewing the outlook and competition concerns as signs of a deeper growth problem and treating the selloff as an overreaction and buying opportunity.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, including its first profit as a public company and rapid AI-compute growth, prompted a rally and a wave of analyst upgrades. Traders are broadly upbeat, while skeptics point to heavy capital spending and upcoming share unlocks; a possible Tesla merger is also being discussed but remains exploratory.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro sharply raised its preliminary fiscal Q1 outlook on stronger AI-platform demand and improved gross-margin expectations, driving a rally. Traders largely welcomed the demand signal and speculated about a short squeeze, while skeptics questioned whether margins, cash flow and execution can sustain the move.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&Ts earnings beat and higher outlook failed to prevent a selloff, with traders pointing to postpaid phone additions falling short of expectations. The reaction is debated as either concern about subscriber momentum and lingering SpaceX competition or an overreaction to otherwise solid results, with some investors buying the dip.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is caught in a sharp memory-chip selloff and rebound debate, with traders pointing to concerns about Chinese competitor CXMT, South Korean market weakness and broader doubts about AI spending. Bulls argue those fears overstate the threat to NAND demand and cite tight memory supply and upcoming earnings, while bears warn that memorys cyclical risks and the wider tech unwind could keep pressure on shares.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings have traders focused on Google Cloud growth and whether AI investments can generate returns, amid widespread concern about heavy capital spending and speculation it could rise further. The debate is split between dip-buyers citing Alphabets AI and cloud businesses and bearish traders worried about spending, search disruption, and the shares persistent weakness.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is drawing attention for its sharp pullback and weak price action ahead of earnings, with traders watching whether cloud growth and AI investment can translate into returns. The discussion is split between dip-buyers citing its AI and quantum-computing progress and bearish traders focused on underperformance, technical support, and heavy capital spending.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives upsized SATS preferred offering and continued Bitcoin purchases are driving attention as the company expands its crypto treasury. Traders are divided between viewing the accumulation as bullish Bitcoin exposure and warning that preferred dividend costs and dilution could weigh on common shareholders.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

SpaceXs strong compute-demand commentary and ambitious capacity plans are driving optimism that AI infrastructure providers such as Nebius can benefit from continued demand. Traders also debate whether the rebound is a durable shift or a short-covering bounce, with concerns about neocloud financing and the sector selloff still weighing on sentiment.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention amid persistent share-price weakness despite community references to ORLADEYO growth and profitable results, fueling criticism of management and calls for buybacks or a sale. Some traders point to future navenibart and Netherton data and continued ORLADEYO growth as potential catalysts, while skeptics focus on dilution, debt and uncertainty around the companys acquisition-led strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sionna Therapeutics, Inc. (SION) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026...

INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION

INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics PR Newswire SAN DIEGO, Aug. 19, 2026 SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law...

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 19, 2026 Sionna Therapeutics Shares Lost Roughly 90% of Their Value After Phase 2a PreciSION CF Trial of SION-719...

Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics...

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Sionna Therapeutics Inc.

SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Sionna said it will not advance SION-719 as an add-on therapy with Trifakta anymore.&nbsp;</li><li>Stifel downgraded Sionna to Hold from Buy with a $7 target, from $55, saying it was “disappointed and very surprised” by the failure.&nbsp;</li><li>Sionna ended the second quarter with about $268 million in cash and said it plans steps to preserve capital while assessing its path forward.</li></ul>Shares of Sionna Therapeutics (SION) plunged roughly 92% on Monday after the biotech firm reported that its experimental cystic fibrosis drug failed to deliver meaningful benefits in a mid-stage trial, prompting it to abandon plans for the treatment as an add-on to existing standard care.Sionna said its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s (VRTX) Trikafta failed to meet its main goal. The drug barely lowered sweat chloride levels—a key marker of improved protein function—showing a minor difference versus placebo that was not statistically significant.The stock is now on track for its worst day ever, if losses hold. VRTX stock, meanwhile, rose 7%, eyeing its best day since early March. &nbsp;<h2 class="st-heading-2">Trial Miss Ends One Program; Another Remains Under Review</h2>Cystic fibrosis is a genetic condition that causes thick mucus to build up in the lungs and other organs, leading to breathing problems and infections. Trikafta is the leading approved treatment. Sionna had hoped SION-719 could further improve outcomes when added on top, but the company said it will not advance the drug in that role anymore after the trial outcomes.The drug was generally well tolerated over 14 days, with mostly mild-to-moderate side effects and no serious issues. Sionna noted possible complicating factors, including unexpected variability in patients’ sweat chloride readings and differences in Trikafta levels during the study periods. It is still analyzing those results.In a separate early-stage study in healthy volunteers, combinations involving Sionna’s related drug SION-451 met safety, tolerability, and exposure goals. The company said it is evaluating next steps for a combination of SION-451 with SION-2222.“We are disappointed in the unexpected results from the Phase 2a trial,” said CEO Mike Cloonan. “We are further evaluating the data to decide on next steps for the SION-451 dual combination.”Sionna ended the second quarter with about $268 million in cash and said it plans steps to preserve capital while assessing its path forward.<h2 class="st-heading-2">Analysts Weigh On VRTX, SION</h2>Wall Street quickly weighed in. Bank of America raised its price target on Vertex to $672 from $605 and kept a ‘Buy’ rating, saying Sionna’s trial miss removes an overhang that investors had viewed as a potential threat to Vertex’s cystic fibrosis franchise.Raymond James downgraded Sionna to ‘Market Perform’ from ‘Strong Buy’, calling the trial a clear failure and citing added uncertainty from possible drug interactions and safety signals.Wedbush cut Sionna to ‘Neutral’ from ‘Outperform’ and lowered its target to $5 from $53, saying that questions remain about the platform’s potential, while shifting any SION-451 launch possibility to 2033.Stifel downgraded Sionna to 'Hold' from 'Buy' with a $7 target, from $55, saying it was “disappointed and very surprised” by the failure and sees no clear Buy case until management explains what went wrong.<h2 class="st-heading-2">How Did SION Retail Traders React?</h2>On Stocktwits, retail sentiment around SION stock jumped from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume rose from 'normal' to 'extremely high' levels.A Stocktwits user highlighted the company’s cash position and termed the stock a steal at current prices.<stembedurl>https://www.stocktwits.com/Invest2live/message/661444973</stembedurl>Another user took a more pessimistic take and wrote, “It may climb from here, but the story is dead.”<stembedurl>https://www.stocktwits.com/CH_Expat/message/661432094</stembedurl><a href="https://stocktwits.com/symbol/SION">SION stock</a> has fallen about 89% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/replimune-s-first-commercial-drug-arrives-with-a-2027-cash-cliff-and-2030-finish-line/cZogtqwRJ96">Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sionna Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sionna said it will not advance SION-719 as an add-on therapy with Trifakta anymore. Stifel downgraded Sionna to Hold from Buy with a $7 target, from $55, saying it was “disappointed and very surprised” by the failure. Sionna ended the second quarter with

Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal.


Sionna Therapeutics Inc

Vertex Pharmaceuticals, Inc.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.22
Prev Close	$4.15
Open	$4.19
Dividend Yield	0.00%
50-Day Moving Average	$5.79
Beta	1.32
Avg. Volume	1.49M
PE Ratio	-1.91

52-Week High	$54.97
52-Week Low	$3.78
Market Capitalization	$187.63M
EPS (Annual)	-$1.68
Price to Book	0.71
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SION Fundamentals